Your SlideShare is downloading. ×
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?
Upcoming SlideShare
Loading in...5
×

Thanks for flagging this SlideShare!

Oops! An error has occurred.

×
Saving this for later? Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime – even offline.
Text the download link to your phone
Standard text messaging rates apply

EUGM 2013 - Steve Hajkowski (Thomson Reuters): Patent analytics - what can Markush data tell us?

1,889

Published on

The presentation will address the variety of industry and scientific trends that patent and more particularly Markush structure data can demonstrate. Case studies will show how structural and other …

The presentation will address the variety of industry and scientific trends that patent and more particularly Markush structure data can demonstrate. Case studies will show how structural and other patent features can help make sense of large and apparently disparate sets of data.

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,889
On Slideshare
0
From Embeds
0
Number of Embeds
2
Actions
Shares
0
Downloads
0
Comments
0
Likes
0
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
No notes for slide

Transcript

  • 1. MARKUSH FOR PATENT ANALYSISSteve HajkowskiChemAxon UGM Budapest 2013
  • 2. THOMSON REUTERS MARKUSH DATA• Indexing for 2.4 million patent families– 1.6m Markush structures, re-drawn & stored in Thomson Reuters vmnfile format– 1.98m specific compounds– plus the corresponding DWPI records– 28 patent issuing authorities covered• backfile from 1978 for US, EP and WO patents– covers pharmaceutical, agrochemical and general chemistry patents• Indexed as part of the editorial process that creates Derwent WorldPatents Index (DWPI)– Informative English language titles & abstracts from worldwide patents– Patent family listing, patent assignees
  • 3. COVERAGE START DATESAustria 1987 Korea 2008Australia 1987 Malaysia 2010Belgium 1987 Netherlands 1987Brazil 2010 New Zealand 1987Canada 1987 PCT/WO1978 (Pharma); 1982 (Agro + Gen.Chem.)China 2008 Poland 2011European Patents1978 (Pharma); 1982 (Agro +Gen. Chem.)Russia 1993-1998 and 2010 to dateFrance1961-1976 (FR-M); 1978(Pharma); 1982 (Agro + GenChem)South Africa 1987Germany1980 (Pharma); 1983-84 and1987 to date (Agro + Gen.Chem.)Spain 2010Great Britain1980 (Pharma); 1983-84 and1987 to date (Agro + Gen.Chem.)Sweden 1987Gulf Cooperation Council 2008 Switzerland 1987India 2000 Thailand 2010Ireland 1987 United States1978 (Pharma); 1982 (Agro + Gen.Chem.)Japan 1987 Vietnam 2010
  • 4. MARKUSH DATA ACCESS• Markush structure data available alongside correspondingspecific compounds & DWPI records• Load into ChemAxon’s JChem database tools• Resulting solution gives access to full chemistry & patentsdataset– data can be searched, enumerated & integrated into thecustomer’s own systems & workflows4
  • 5. JCHEM MARKUSH BENEFITS• Structure data displayed alongside high qualitypatent summaries from DWPI– includes abstract, patent assignee, patent family, activities& mechanisms of action• Time saving visualisation and enumerationcapabilities enable fast relevance analysis of hitstructures/patents• Enumerated structures are in standard formatallowing easy integration with other chemistrydatasets/tools
  • 6. USE CASES• Novelty searching by IP departments– Easy assessment of structural proximity of query structureto hit Markush• Screening of new structures against existing IP• Potential use in white-space identification, patentbusting etc.• Creation of libraries of specifics for use in othersystems
  • 7. MARKUSH PATENT ANALYSIS• What can analysis of Markush and DWPI patent datatell us about global patenting trends in 2012?• > 8000 patents claiming new pharmaceutical Markushstructures• > 3700 patents claiming new non-pharma Markushstructures
  • 8. MARKUSH PHARMA PATENTINGCOMPANIES 2012Number of patents Company129 MERCK & CO119 ROCHE82 BAYER AG60 ABBOTT59 GLAXOSMITHKLINE57 NOVARTIS57 CENTRE NATIONAL RECHERCHE SCIENTIFIQUE55 BOEHRINGER INGELHEIM54 SANOFI AVENTIS52 BRISTOL-MYERS SQUIBB51 MERCK PATENT GMBH42 JOHNSON & JOHNSON41 ALLERGAN39 TAKEDA PHARMA37 PFIZER30 COUNCIL SCI&IND RES INDIA27 SHIONOGI26 DAIICHI SANKYO25 UNIV CALIFORNIA
  • 9. MARKUSH PHARMA PATENTINGTERRITORIES IN 2012
  • 10. MARKUSH CHEMICAL PATENTINGCOMPANIES 2012Number of patents Company164 SUMITOMO CHEMICAL CO90 BAYER CROPSCIENCE82 BASF65 MERCK PATENT GMBH61 FUJI FILM CO42 SEMICONDUCTOR ENERGY LAB40 SYNGENTA39 ROHM&HAAS ELECTRONIC MATERIALS KOREA38 CANON KK38 OCEANS KING LIGHTING SCI&TECHNOLOGY CO37 IDEMITSU KOSAN CO LTD36 DU PONT34 HAIYANGWANG LIGHTING TECHNOLOGY CO LTD34 NIPPON KAYAKU KK34 POLITECHNIKA WROCLAWSKA30 JNC CORP28 KOREA RES INST CHEM TECHNOLOGY27 TOSOH CORP26 TIANJIN DEKAI CHEM LTD
  • 11. MARKUSH CHEMICAL PATENTINGTERRITORIES IN 2012
  • 12. MARKUSH CASE STUDY• Analysis of all Markush patents claiming newmolecules containing the structure fragment below– look at companies, timeframes, activities, inventors
  • 13. SEARCH RESULTS• A structure search of the Thomson Reuters datagenerates hits from 122 patents, with hits foundback to 1988
  • 14. SAMPLE HITSNew heterocyclic derivatives useful for treating cardiovasculardiseases,hypertension, ischemic heart disease,atherosclerosis and metabolic syndromeCTG PHARMA SRL WO2008122356A1 20081016Novel benzyloxymethyl-4-chloro-imidazolmethyl-biphenyl-tetrazole group containing compounduseful for treating diseases associated withperoxisomeproliferator-activated receptor-gamma, e.g. diabetes andangiocardiopathySHANGHAI AILISI MEDICINE SCI & TECHNOLOGYWO2008110062A1 20080918
  • 15. SAMPLE HITSNew 2-butyl-4-chloro-imidazol-5-yl-methyl estercompound used for preparing drugs for prophylaxisand/or treating high blood pressure or correlativediseases including pulmonary arterial hypertension,coronary heart disease and/or migraineWANG J CN101475565A 20090708Forming biphenyltetrazole derivatives useful to treat e.g.stroke involves reacting 2-(trimethylsilyl)ethoxymethylprotected biphenyltetrazole compounds with nucleophilicreagent and subsequent deprotection ofprotecting groupSIMS SOC ITAL MEDICINALI SCANDICCI SRLWO--2008012852A1
  • 16. TOP 10 COMPANIESNumber of patents Company17 MERCK & CO INC8 NICOX SA7 DU PONT DE NEMOURS & CO7 KOTOBUKI SEIYAKU CO LTD6 MERCK PATENT GMBH4 NITROMED INC4 TANABE SEIYAKU CO4 THERAVANCE INC3 DIPHARMA SPA3 SANKYO CO LTD
  • 17. TOP PATENT COUNTRIES
  • 18. PATENTING TIMELINE
  • 19. DRUG ACTIVITIES CLAIMED% of Patents Activity88 Hypotensive64 Cardioactive47 Renal active43 Anti-cholesterol43 Eye preparations34 Circulatory active32 Antipsychotic30 Coronary dilator28 Antimetabolite27 Antiinflammatory25 Enzyme inhibitor
  • 20. TOP INVENTORS AT MERCKNumber of patents Inventor9 LO M M8 ALI A6 ALMIRANTE N5 STEFANINI S4 BIONDI S4 CHAKRAVARTY P K4 FRANKLIN C4 GREENLEE W J4 NARGUND R P4 PATCHETT A A4 SEBHAT I K
  • 21. SUMMARY• Markush analysis allows us to view the chemistrypatent lansdcape– broad view of trends for companies, countries etc– narrower view for particular structure types• shows which companies are active, trends over time, topinventors, drug activities etc.
  • 22. Thank you

×